The company says I2E 3.0 provides accessible text mining, enabling research and business decision-makers to uncover relevant insights by extracting key facts and relationships from document collections. According
Emend (fosaprepitant dimeglumine) for injection is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial
The FDA communicated a refusal to file, citing several issues including the adequacy of the analytical methodology to characterize the active pharmaceutical ingredient of Coprexa; a request to
The agreement, under the FDA’s special protocol assessment (SPA) process, affirms that the LibiGel Phase III clinical trial design, clinical endpoints, sample size, planned conduct and statistical analyses
Published online in Blood by the Burnham Institute’s president and CEO, John Reed and collaborators, the paper summarized study findings demonstrating that mice treated with apogossypol experienced less
Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism. ImaRx is continuing its stability program to evaluate the potential for further
Clexane is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis. The recommended dose regimen
The study findings demonstrate that mice treated with Apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with Gossypol. The results support Coronado Biosciences’ continued development of
In pre-clinical trials, BL-1021 showed a significant reduction in symptoms of neuropathic pain with reduced side effects. The molecule was given orally and in all cases was found
Under the terms of the licensing agreement, Gastrotech will receive a global exclusive license to develop and market GTP-010 for irritable bowel syndrome (IBS) and functional dyspepsia. Lilly
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.